Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
You may also be interested in...
EW Healthcare Partners Adds Women’s Health Heft With TherapeuticsMD Buyout
Deal Snapshot: The UK-based private equity firm will acquire troubled specialty pharma TherapeuticsMD for roughly $177m, after the company’s three-product portfolio yielded revenues of $85.8m in 2021.
Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications
The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.
Finance Watch: Exscientia Launches Last IPO Of Q3, Brings US Total To 88
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.